UNSPSC 51182701: Glimepiride/pioglitazone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182701 Glimepiride/pioglitazone is a Commodity code whose recent state and local activity shows little direct alignment with its pharmaceutical compound scope. The single substantive opportunity tagged under this code—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—involves emergency-response and harm-reduction supplies rather than the diabetes medication combination the code nominates. The Texas Health and Human Services Commission's RFI HHS0017013 on Direct-to-Manufacturer Prescriptions, also tagged to this code, explores pharmacy benefit program architecture and manufacturer relationships but does not specify particular drugs or formulations. State and local buyers soliciting under this code have not shown a pattern of purchasing glimepiride/pioglitazone combinations as a category; the mismatch between code nomenclature and actual procurement activity suggests either coding inconsistency in the source records or that this specific pharmaceutical combination sees minimal state and local procurement volume at present.

Seminole County and the Texas HHS Commission represent the only recent issuers identified. Geographically, the recent activity spans Florida and Texas only, with no other jurisdictions appearing in the available records. The Seminole County solicitation (due July 26, 2023) sought annual quantities of 1,900 units of naloxone and 800 deactivation systems with quarterly deliveries and a two-year initial contract term plus one-year renewal option. The Texas RFI (response deadline April 3, 2026) functioned as preliminary market intelligence gathering rather than a formal bid solicitation, designed to shape future pharmacy benefit procurement strategy. Neither opportunity directly targets the glimepiride/pioglitazone combination that the code nominates, and no additional state or local opportunities under this code appear in the recent-activity record.